Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors (Q33923397)

30 July 2017

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors (English)

1 reference

30 July 2017

1 reference

Patricia M Lorusso

1

1 reference

30 July 2017

Martin J Edelman

2

1 reference

30 July 2017

Susan L Bever

3

1 reference

30 July 2017

Karen M Forman

4

1 reference

30 July 2017

Maryjo Pilat

5

1 reference

30 July 2017

Mary F Quinn

6

1 reference

30 July 2017

Jing Li

7

1 reference

30 July 2017

Elisabeth I Heath

8

1 reference

30 July 2017

Lisa M Malburg

9

1 reference

30 July 2017

Patrick J Klein

10

1 reference

30 July 2017

Christopher P Leamon

11

1 reference

30 July 2017

Richard A Messmann

12

1 reference

30 July 2017

Edward A Sausville

13

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

Journal of Clinical Oncology

30 July 2017

1 reference

30 July 2017

30

1 reference

30 July 2017

32

1 reference

30 July 2017

4011-4016

1 reference

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Caveolae--an alternative endocytotic pathway for targeted drug delivery.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Toxicity patterns of cytotoxic drugs.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Targeting of porous hybrid silica nanoparticles to cancer cells

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Folate receptor specific anti-tumor activity of folate-mitomycin conjugates

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104289

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer

29 October 2018

1 reference

12 December 2020

Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide

1 reference

12 December 2020

Spontaneous generation of giant liposomes from an oil/water interface

1 reference

12 December 2020

Selective delivery of folate–PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft: Effect of chain length and amount of folate–PEG linker

1 reference

12 December 2020

Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications

1 reference

12 December 2020

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2011.41.4946

1 reference

30 July 2017

1 reference

30 July 2017

1 reference